Welcome to our dedicated page for CEAPRO news (Ticker: CRPOF), a resource for investors and traders seeking the latest updates and insights on CEAPRO stock.
Ceapro Inc (CRPOF) is a Canadian biotechnology company specializing in the development of proprietary extraction technology for producing extracts and active ingredients from oats and other plant resources. The company supports the use of its extracts in cosmeceutical, nutraceutical, and therapeutic products for human and animal health. Ceapro leverages its expertise in natural product chemistry, microbiology, biochemistry, immunology, and process engineering to create active ingredients, biopharmaceuticals, and drug-delivery solutions. Visit Ceapro's website for more information.
Ceapro reported record sales for Q2 2022, with revenues reaching $5,500,000, a 25% increase from Q2 2021. Year-to-date sales rose 28% to $11,672,000. Income before tax soared to $2,177,000 in Q2, a 322% jump year-over-year, with year-to-date income at $4,790,000, up 302%. Strong sales growth was mainly driven by a 23% increase in avenanthramides and 75% for beta glucan. The company is advancing multiple products through clinical trials and enhancing its technology for greater efficiency.
Ceapro (CRPOF) announced an expanded research project with McMaster University to develop an inhalable treatment for COVID-19-induced lung fibrosis using PGX-Processed yeast beta-glucan. This project continues a collaboration initiated in 2019 focused on drug delivery systems for unmet medical needs. Dr. Martin Kolb will co-lead the initiative alongside Drs. Ask and Hoare. The goal is to optimize the delivery of PGX-YBG for clinical trials, addressing the significant issue of pulmonary fibrosis. Funding for three post-graduate students will be provided through a collaboration with Mitacs.
Ceapro (CRPOF) announced the acceptance of positive results from a collaborative study with the University of Alberta, detailing the development of superior bioactive delivery systems using its PGX technology. Published in The Journal of Supercritical Fluids, the study highlights how PGX-processed Sodium Alginate (SA) allows for higher loading of coenzyme Q10 (CoQ10), enhancing its bioavailability. The findings bolster Ceapro's potential to expand its product pipeline, offering better CoQ10 supplements, crucial for cellular functions, particularly for individuals over 40.
Ceapro Inc. (OTCQX: CRPOF) announces the appointment of Sigrun Watson as Chief Revenue Officer. Watson brings over 20 years of healthcare management experience, focusing on corporate strategy in Cosmeceutical and Nutraceutical sectors. Her previous roles include Vice President at Inagene Diagnostics and leadership positions at major pharmaceutical companies. CEO Gilles Gagnon emphasized her relevant background in pharma and nutrition as pivotal for Ceapro's next growth phase. Watson aims to contribute significantly to the company's ongoing success.
Ceapro Inc. (OTCQX: CRPOF) announced the election of its Directors for a one-year term during its Annual General and Special Meeting held on June 1, 2022. Key votes included Genevieve Foster receiving 95.21% approval and Gilles Gagnon with 66.63%. Additionally, shareholders approved the appointment of auditors and an amended Stock Option Plan. Ronnie Miller will serve as Chairman, while Foster heads the Audit Committee. Ceapro focuses on developing active ingredients from oats and plant resources for healthcare and cosmetics, leveraging its proprietary extraction technology.
Ceapro Inc. (OTCQX: CRPOF) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL. Gilles Gagnon, CEO, will present and engage in virtual one-on-one meetings with investors. A video webcast of the presentation will be available on-demand starting May 24, 2022, at 7:00 AM ET, archived for 90 days. Ceapro focuses on developing active ingredients from oats and renewable plant resources, serving healthcare and cosmetic sectors. Learn more at ceapro.com.
Ceapro reported its Q1 2022 financial results, achieving all-time high sales of $6,172,000, a 31% increase from $4,702,000 in Q1 2021. The operating profit surged to $2,614,000, compared to $515,000 last year. The company doubled its output to meet the rising demand and signed a three-year supply agreement with Symrise Group for enhanced revenue stability. Their R&D focus is on avenanthramides, alginate, and yeast beta glucan, boasting promising developments for clinical applications.
Ceapro (OTCQX: CRPOF) continues to innovate in biotechnology with its patented PGX Technology, showcased by Dr. Bernhard Seifried at the upcoming ISSF 2022 in Montréal. This technology efficiently produces novel bioactive delivery systems for nutraceuticals and wound healing, processing challenging high-molecular-weight biopolymers without conventional lengthy steps. PGX Technology allows rapid creation of customizable composites, enhancing Ceapro's ability to cater to healthcare and cosmetic industries. The University of Alberta’s licensing provides exclusive rights for industrial applications.
Ceapro (CRPOF) announces the publication of research on its PGX Technology, a method that transforms brown algae alginates into highly effective and bioactive delivery systems. This innovative technology increases the surface area of alginates by 90 times and produces unique fibrous structures, setting the stage for advancements in healthcare and cosmetics. The study, conducted with the University of Alberta, confirms PGX Technology's scalability and effectiveness compared to traditional methods, enhancing the company’s strategic assets.
Ceapro (TSX-V: CZO, OTCQX: CRPOF) announced the appointment of Geneviève Foster to its Board of Directors, bringing over 20 years of experience in life sciences and pharma. Foster has a strong track record in negotiating strategic transactions and legal affairs. Her expertise aligns with Ceapro's growth goals, particularly in expanding into nutraceuticals and pharmaceuticals. With this appointment, she was granted options for 150,000 common shares, vesting over three years. Ceapro focuses on developing active ingredients for healthcare and cosmetic applications.
FAQ
What is the current stock price of CEAPRO (CRPOF)?
What is the market cap of CEAPRO (CRPOF)?
What is Ceapro Inc?
What products does Ceapro specialize in?
What expertise does Ceapro have?
Where can I get more information about Ceapro Inc?
